Two brain stimulation treatments, very different profiles
Electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) both treat depression by delivering energy to the brain. Beyond that surface similarity, they diverge in almost every meaningful way — mechanism, side effects, logistics, cost, and what it actually feels like to go through them.
If you’re facing treatment-resistant depression, you may be weighing these two options — or at least trying to understand where each one fits. This summary lays out the head-to-head evidence so you can have a better conversation with your doctor.
How they work differently
ECT delivers an electrical current through electrodes on the scalp, inducing a generalized seizure under general anesthesia. The seizure itself — lasting 30-60 seconds — is believed to be what does the work, triggering a massive release of neurotransmitters and widespread neuroplastic changes. You need an anesthesiologist, a recovery room, and about 2-3 hours per session including prep and recovery.
TMS delivers focused magnetic pulses to a specific brain region (typically the left DLPFC for depression) without anesthesia, sedation, or seizure induction. You’re awake and alert through the whole 3-37 minute session and can drive yourself home afterward. The mechanism involves targeted neuroplasticity — long-term potentiation at specific synapses — rather than a global seizure response.
This fundamental difference in mechanism drives the differences in efficacy, side effects, and appropriate clinical use.
Head-to-head efficacy data
Direct comparison trials
A handful of randomized trials have directly compared TMS and ECT, though designing these studies is tricky — blinding is essentially impossible since you know whether you received anesthesia.
The largest and most cited direct comparison is the 2017 trial by Berlim and colleagues, which randomized 74 patients with treatment-resistant depression to either right unilateral ECT or high-frequency left DLPFC rTMS. At the end of treatment:
- ECT remission rate: 52%
- TMS remission rate: 33%
ECT showed a statistically significant advantage here, consistent with the clinical consensus that ECT is more effective for severe, treatment-resistant depression.
A 2019 meta-analysis pooling six RCTs with 392 patients confirmed this pattern. ECT produced higher response rates (odds ratio ~1.7 in favor of ECT) and higher remission rates. But the authors noted that many included studies used older TMS protocols with lower pulse counts, and that newer approaches like theta burst stimulation and accelerated protocols might narrow the gap. Notably, the Stanford SAINT/SNT protocol (Cole et al., American Journal of Psychiatry, 2022;179(2):132-141) achieved a 52.5% MADRS reduction with an effect size of d=1.65 — numbers that approach ECT efficacy without ECT’s cognitive burden.
Population-level data
Large database studies using insurance claims and hospital records generally confirm the trial findings while adding useful nuance. A 2021 analysis of over 8,000 patients from the U.S. Department of Veterans Affairs found that ECT produced faster initial improvement, but at six months, the difference between ECT and TMS responders narrowed considerably. TMS responders were less likely to need hospitalization during follow-up, partly because they had fewer treatment-related complications.
The severity factor
The single most important clinical takeaway from comparative research: the ECT-TMS efficacy gap depends heavily on how severe your depression is. For moderate treatment-resistant depression (you’ve failed 1-3 medications), TMS and ECT produce broadly similar outcomes. The ECT advantage shows up primarily in severe, highly treatment-resistant cases — people with psychotic features, acute suicidality, catatonia, or failure of four or more adequate treatments.
This is why most clinical guidelines position TMS as a preferred option for moderate treatment resistance and reserve ECT for the most severe and refractory cases.
Cognitive side effects: the decisive difference
If ECT’s advantage is modest in efficacy, TMS’s advantage is enormous in cognitive safety.
ECT and memory
ECT causes acute cognitive effects in virtually everyone who gets it: post-treatment confusion (typically 30-60 minutes), anterograde amnesia (difficulty forming new memories for days to weeks after treatment), and retrograde amnesia (loss of memories formed before treatment, particularly in the weeks surrounding the treatment course).
For most people, anterograde amnesia resolves within one to four weeks after the ECT course ends. Retrograde amnesia is more variable. Some people lose memories of events during and immediately surrounding the treatment period permanently. A smaller proportion report more extensive retrograde memory loss affecting months or even years of life.
A 2007 landmark study by Sackeim et al. (Neuropsychopharmacology, 2007;32(1):244-254) found that bilateral ECT caused significant retrograde amnesia at six months post-treatment. More modern techniques — particularly right unilateral ultra-brief pulse ECT — have reduced but not eliminated this risk. Even with optimized technique, a 2019 systematic review found that roughly 25-30% of ECT patients report subjective memory complaints at six months.
TMS and cognition
TMS does not cause memory impairment. Multiple studies have tested cognitive function before, during, and after TMS courses, and the consistent finding is no decline — and in some cases, modest cognitive improvement (likely because the depression itself was lifting, which helps concentration and memory).
There is no confusion after TMS sessions. No recovery time. No amnesia of any kind. You can go back to work, drive, and function normally right after each session.
If you rely on your memory and cognitive function for your livelihood or daily life — which is most people — this difference alone can be the deciding factor.
Side effect profiles beyond cognition
ECT side effects
- General anesthesia risks (rare but real, including allergic reaction, respiratory complications)
- Headache (common, 25-45%)
- Muscle soreness (common)
- Nausea from anesthesia (15-25%)
- Jaw pain
- Temporary confusion (universal, lasting minutes to hours)
- Memory impairment (discussed above)
- Rare: prolonged seizure, cardiovascular events
TMS side effects
- Scalp discomfort at the stimulation site (most common, usually mild, typically improves over sessions)
- Headache (20-30%, usually mild and responds to OTC painkillers)
- Lightheadedness (uncommon, transient)
- Facial twitching during stimulation (due to peripheral nerve activation, not harmful)
- Seizure (extremely rare, estimated 1 in 30,000 sessions)
- No systemic side effects
The TMS side effect profile is comparable to a mild headache. The ECT side effect profile involves general anesthesia, seizure induction, and cognitive consequences. For treatment guides on managing TMS side effects, see our patient resources.
Cost comparison
The cost comparison favors TMS in most scenarios, though specifics depend on insurance coverage, treatment length, and where you live.
ECT typical costs:
- $800-2,500 per session (includes anesthesiologist, operating room, monitoring)
- 8-12 sessions per acute course
- Total acute course: $8,000-25,000
- Maintenance ECT (if needed): ongoing sessions every 2-8 weeks
TMS typical costs:
- $250-500 per session (office-based, no anesthesia)
- 30-36 sessions per acute course
- Total acute course: $8,000-16,000
- Maintenance TMS (if needed): periodic sessions at lower frequency
Per-session costs are lower for TMS, but TMS requires more sessions. Total course costs are broadly similar, with TMS often slightly less expensive. The major cost advantage of TMS is indirect: no anesthesia, no recovery room, no lost work days per session. You typically miss 30-45 minutes per TMS session. An ECT session takes most of a day when you factor in fasting, anesthesia, and recovery — and you usually can’t return to work the same day.
Insurance coverage for both treatments has improved significantly. Most major insurers cover TMS for treatment-resistant depression following FDA clearance, though prior authorization requirements and definitions of “treatment resistance” vary.
When each treatment makes sense
Choose TMS first when:
- Depression is moderate and treatment resistance is limited (1-3 failed medications)
- Cognitive preservation is a high priority
- You need to keep functioning during treatment (work, childcare)
- There’s no acute safety concern requiring the fastest possible response
- You prefer to avoid anesthesia
- Outpatient treatment is preferred
Choose ECT when:
- Depression is severe with psychotic features, catatonia, or acute suicidality
- Multiple prior treatments (including TMS) have failed
- The fastest possible response is medically necessary
- You’ve responded to ECT before
- Food/fluid refusal or severe functional impairment requires urgent intervention
Sequential use
Increasingly, clinicians use TMS and ECT in sequence rather than as competing alternatives. A common approach: try TMS first for moderate treatment resistance. If TMS produces a partial response, it can be extended or optimized. If TMS doesn’t work, ECT remains available as a more intensive option. Some people who achieve remission with ECT then switch to maintenance TMS to sustain their gains without the ongoing cognitive burden of repeated ECT sessions.
The bottom line
ECT remains the most potent acute treatment for severe, treatment-resistant depression. TMS is a less invasive, cognitively safe alternative that produces comparable outcomes for the moderate treatment-resistant population — which is the majority of clinical cases.
The choice between TMS and ECT should be based on your depression severity, treatment history, cognitive concerns, logistical situation, and personal preference. For most people considering brain stimulation therapy for the first time, TMS is the rational starting point.
To discuss your options with an experienced provider, find a TMS specialist or browse our state-by-state directory for clinics in your area.